The impact of oral medications on weight change was mostly similar in type 3c diabetes and T2D, although small differences for sulphonylureas and SGLT2‐inhibitors in those with PEI were observed, these are unlikely to be clinically significant. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.